See what’s new.
Transforming inventions into products: Duke charts a path for student innovators
Duke’s innovation ecosystem collaborates to offer Duke graduate and professional students a hands-on technology commercialization bootcamp – focused on student-led inventions.
BMI OrganBank, Atrium Health and LifeShare Carolinas Partner to Launch Nation’s First Organ Banking Technology
BMI OrganBank licensed perfusion tech from the Duke Ex-Vivo Organ Lab, led by Drs. Andrew S. Barbas and Matthew Hartwig (Surgery, SOM).
FDA and EMA Accept Vorasidenib Regulatory Submissions for the Treatment of IDH-mutant diffuse glioma
This application of vorasidenib is based on licensed technology developed by Dr. Darell Bigner (Neurobiology, SOM) and colleagues.
How Stefan Roberts and inSoma Bio are upgrading fat grafting with Duke technology and support
Learn how the Duke community is helping BME Ph.D. graduate Stefan Roberts and his start-up inSoma Bio commercialize technology he developed in the lab of Professor Ashutosh Chilkoti.
Basking Biosciences Announces Close of $55 Million Financing to Accelerate Clinical Development for First Reversible Thrombolytic for Ischemic Stroke
Basking Biosciences, a start-up out of the lab of Professor Bruce Sullenger (Surgery, SOM), is developing a next-gen treatment for stroke.
Duke is Inventive: A Century of Innovation at Duke University
A new Centennial physical and digital exhibit from OTC collects innovations, inventors, and companies spinning out of Duke University.
Humacyte Submits Biologics License Application (BLA) to U.S. FDA Seeking Approval of Human Acellular Vessel™ (HAV™) for the Treatment of Vascular Trauma
Humacyte is a Duke University start-up out of the lab of Dr. Laura Niklason (formerly Anesthesiology, SOM), co-founded with Drs. Juliana Blum and Shannon Dahl.
Ten63 Therapeutics Announces Multi-Target Drug Discovery Collaboration with Boehringer Ingelheim
Ten63 is a Duke University start-up and DCP portfolio company out of the lab of Professor Bruce Donald (Computer Science, Trinity).
Tune Therapeutics Presents First Data Supporting TUNE-401: a First-in-Class Epigenetic Silencer for Hepatitis B
Tune Therapeutics is a Duke start-up and DCP portfolio company developing epigenetic editing spun out of the lab of co-founder Professor Charles Gersbach (BME, Pratt).